# ALT — Altimmune Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALT  
**Sources:** 19  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alt-altimmune-inc-catalysts-narrative-risks-5989

---

# Altimmune Inc. (NASDAQ: ALT) — Research Snapshot (as of 2026-10-04)

## Company Baseline
Altimmune is a late clinical-stage biopharmaceutical company developing **pemvidutide**, a dual glucagon/GLP-1 receptor agonist, across three liver-disease indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). It generates essentially no product revenue, so its value is tied to clinical, regulatory, and financing milestones rather than commercial sales [[9]](https://deltasheets.substack.com/p/alt-fy2026-q2), [[10]](https://finance.yahoo.com/healthcare/articles/altimmune-alt-three-liver-trials-022735658.html), [[11]](https://www.insidermonkey.com/blog/altimmunes-alt-three-liver-trials-move-forward-at-once-1829744/), [[12]](https://finance.yahoo.com/healthcare/articles/altimmune-alt-three-liver-trials-022735658.html). Market cap was ~$556.3 million and the stock traded around $3.00 as of late 2026 [[9]](https://deltasheets.substack.com/p/alt-fy2026-q2).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alt-altimmune-inc-catalysts-narrative-risks-5989 (free to sign up)._
